论文部分内容阅读
目的:观察骨化三醇冲击治疗尿毒症继发性甲状旁腺功能亢进的疗效和安全性。方法:100例尿毒症维持性血液透析患者随机分为两组。对照组50例采用常规剂量骨化三醇治疗,观察组50例采用骨化三醇冲击治疗。治疗8周后,比较两组患者血清钙(Ca)、磷(P)、全段甲状旁腺激素(i PTH)、钙磷乘积(Ca×P)等指标水平变化,评价两组临床疗效和药品不良反应。结果:治疗后,观察组临床总有效率高于对照组(P<0.05);两组血清i PTH水平均较前下降,而血清Ca水平则较前升高(P<0.05),且观察组i PTH水平明显低于对照组,Ca水平则明显高于对照组(P<0.01)。两组不良反应率比较,差异无统计学意义(P>0.05)。讨论:骨化三醇冲击治疗尿毒症继发性甲状旁腺功能亢进临床疗效较好,且安全,值得临床推广。
Objective: To observe the efficacy and safety of calcitriol shock in the treatment of secondary hyperparathyroidism of uremia. Methods: 100 patients with uremic maintenance hemodialysis were randomly divided into two groups. Fifty patients in the control group were treated with conventional calcitriol and 50 patients in the observation group were treated with calcitriol. After 8 weeks of treatment, the changes of serum Ca, P, i PTH and Ca × P were compared between the two groups to evaluate the clinical efficacy and Adverse drug reactions. Results: After treatment, the clinical total effective rate in the observation group was higher than that in the control group (P <0.05). The levels of serum i PTH in both groups were lower than those in the control group, while the levels of serum Ca in the observation group were higher than those in the control group (P <0.05) i PTH levels were significantly lower than the control group, Ca levels were significantly higher than the control group (P <0.01). Adverse reactions between the two groups, the difference was not statistically significant (P> 0.05). Discussion: calcitriol treatment of uremia secondary hyperparathyroidism clinical efficacy is better, and safe, worthy of clinical promotion.